NCT04782115已完成2 期
Protein by Dual Blockage of VEGF and FGF-2) in Subjects With Diabetic Macular Edema.
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 156
- 试验地点
- 37
- 主要终点
- Mean change from baseline in BCVA at 52 week;
研究概览
简要总结
This is a non-randomized, open-label, multicenter, 48-week study to investigate the efficacy, safety and pharmacokinetics of RC28-E injection in the treatment of patients with diabetic macular edema.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Sign the consent form, willing and able to comply with clinic visits and study-related procedures;
- •Aged 18 years to 80 years, male or female;
- •Diabetes mellitus(type 1 or 2);
- •The study eye must followed:
- •Retinal thickening secondary to diabetes mellitus (DME) involving the center of the fovea; Decrease in vision determined to be primarily the result of DME and not to other causes.
- •BCVA score in the study eye of 73 to 24 using the ETDRS protocol at an initial testing distance of 4 meters.
- •The central subfield thickness ≥300μm in the center subfield as assessed on OCT by the reading center;
- •If both eyes meet the inclusion criterion, one eye with poor BCVA is selected as the study eye; the researchers judged that the fellow eye should not be treated with other anti-VEGF drugs recently.
排除标准
- •The macular edema caused by others instead of diabetes mellitus;
- •Structural damage to the center of the macula in the study eye that is likely to preclude improvement in BCVA following the resolution of macular edema including atrophy of the retinal pigment epithelium, subretinal fibrosis or scar, significant macular ischemia or organized hard exudates;
- •Current iris neovascularization, vitreous hemorrhage, tractional retinal detachment or epiretinal membrane involving the macula in the study eye;
- •Only one functional eye even if that eye is otherwise eligible for the study;
- •Evidence of periocular or intraocular inflammation or infection including infectious blepharitis, keratitis, scleritis, conjunctivitis, endophthalmitis or uveitis at screening assessment in either eye;
- •Previous treatment with anti-angiogenic drugs in either eye or system (ranibizumab, aflibercept, conbercept, etc) within 3 months of the Day 0;
- •History of cardiovascular and cerebrovascular events within 6 months of screening visit: myocardial infarction, unstable angina pectoris, ventricular arrhythmias, New York heart association grade II + heart failure, stroke, etc.;
- •Uncontrolled clinical disease (such as severe psychiatric, neurological, cardiovascular, respiratory disease or other systemic diseases) and tumors;
- •Those who participated in clinical trials for 3 months or 5 half-lives of the investigational product (the longer the time) before the baseline period;
- •Those who considered unsuitable for enrollment by investigator.
结局指标
主要结局
Mean change from baseline in BCVA at 52 week;
时间窗: Baseline, Week 52
Measurement of visual acuity with Early Treatment Diabetic Retinopathy Study (ETDRS) charts.
Mean change from baseline in BCVA at 24 week;
时间窗: Baseline,week 24
BCVA=Best-corrected visual acuity;Measurement of visual acuity with Early Treatment Diabetic Retinopathy Study (ETDRS) charts.
次要结局
- Safety of RC28-E injection(Baseline up to Week 52)
- Percentage of subjects with VA worsen (who lost ≥5 letters, ≥10 letters, ≥15 letters in their BCVA) from baseline at 52 week;(Baseline, Week 52)
- Mean change from baseline in BCVA at every visit during treatment period;(Baseline up to Week 52)
- Percentage of subjects with BCVA ≥ 68 letters(a visual acuity Snellen equivalent of 20/40 or better) at 52 week;(Baseline, Week 52)
- Frequency of administration RC28-E;(Baseline, Week 52)
- Mean change from baseline in central subfield thickness at 12, 24, 36, 52 week.(12, 24, 36, 52 week.)
- Percentage of subjects with VA improvement (who gained >0 letters, ≥5 letters, ≥10 letters, ≥ 15 letters in their BCVA) from baseline at 52 week;(Baseline up to Week 52)
研究者
研究点 (37)
Loading locations...
相似试验
已完成
2 期
Phase II/III Study of Anti-VEGF in Neovascular AMDMacular DegenerationChoroidal NeovascularizationNCT00021736Eyetech Pharmaceuticals540
已完成
1 期
Study of Oral Lucitanib (E-3810), a Dual VEGFR-FGFR Tyrosine Kinase Inhibitor, in Patients With Solid TumorsSolid TumorsNCT01283945Institut de Recherches Internationales Servier134
Unknown
4 期
Efficacy and Safety of Two Regimens of Anti-VEGF Therapy in Chinese Patients With Polypoidal Choroidal VasculopathyPolypoidal Choroidal VasculopathyNCT04380974Xiaodong Sun102
已完成
3 期
Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration (AMD)Macular DegenerationNCT00637377Bayer1,240
已完成
2 期
VEGF Trap in Treating Patients With Recurrent, Locally Advanced, or Metastatic Cancer of the UrotheliumAdenocarcinoma of the BladderDistal Urethral CancerMetastatic Transitional Cell Cancer of the Renal Pelvis and UreterProximal Urethral CancerRecurrent Bladder CancerRecurrent Transitional Cell Cancer of the Renal Pelvis and UreterRecurrent Urethral CancerSquamous Cell Carcinoma of the BladderStage III Bladder CancerStage III Urethral CancerStage IV Bladder CancerTransitional Cell Carcinoma of the BladderUrethral Cancer Associated With Invasive Bladder CancerNCT00407485National Cancer Institute (NCI)22